Two gene-editing trial deaths in China expose oversight gaps

Two deaths in Chinese gene-editing trials within half a month have raised questions about whether regulatory oversight has kept pace with the country's rapid biotech expansion, as authorities launch probes into both cases.

"The goal of regulation is not to impede scientific research, but to eliminate reckless human experimentation and prevent the entire industry from stagnating because of individual malicious incidents," Shi Jiayou, a professor at Renmin University of China Law School, told The Beijing News. "The lives and safety of research participants must always take priority over world's firsts, journal publications and academic breakthroughs."

Shanghai-based HuidaGene Therapeutics disclosed Aug. 5 that a child with Duchenne muscular dystrophy died in August 2025 after receiving HG302, its gene-editing therapy delivered via adeno-associated virus (AAV) vectors. The company attributed the death to acute respiratory distress syndrome triggered by a severe immune reaction to high-dose AAV administration. The patient was the fourth and last participant in the first-in-human trial, which enrolled boys aged four to eight.

The disclosure follows a separate case in which a 6-year-old girl died March 31, 2025, after receiving what researchers called the world's first brain-directed gene-editing therapy at Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The girl, who had Snijders Blok-Campeau syndrome, died from thrombotic microangiopathy — a condition where tiny blood clots form in small blood vessels. The death was not publicly disclosed until Science and Retraction Watch published an investigation July 23.

High-dose AAV vectors carry known risks

HuidaGene said the fatal event was reported through the hospital's ethics and study-oversight processes "within the applicable reporting time frame after the site became aware of it, in accordance with good clinical practice." The analysis was submitted for peer review in January, with findings to be shared upon publication.

High-dose AAV administration has caused fatal immune reactions in other clinical trials globally, including in young boys with Duchenne muscular dystrophy. The therapy uses modified viruses to deliver DNA-editing components to cells, and the patient in HuidaGene's trial received a high dose, which the company said triggered severe complement and cytokine activation leading to acute respiratory distress syndrome.

Investigator-initiated trials bypass national oversight

The Xinhua Hospital case highlights the opaque nature of China's investigator-initiated trial (IIT) system, which permits researchers at major hospitals to test novel therapies without approval from the national drug regulator. Such studies have surged in recent years, helping accelerate development of cell and gene therapies that are fueling China's biotech boom.

The research team, led by Qiu Zilong, a neuroscientist at Shanghai Jiao Tong University School of Medicine, claimed the trial was the world's first human test of its kind, with the girl as its only participant. According to the investigative report, the published research failed to disclose liver and kidney damage observed during prior safety studies in nonhuman primates. An internal ethics review at Xinhua Hospital concluded the girl's death was "definitely related" to the treatment, yet trial leaders did not publicly disclose her death or update the clinical trial registry.

In February, the research team published preclinical findings in the journal Nature without disclosing either the human trial or the girl's death. On July 29, Nature added an editorial note saying concerns had been raised about the publication and its data. On July 30, the trial was marked as terminated on ClinicalTrials.gov, with a notation stating the single participant died from thrombotic microangiopathy, "a serious adverse event assessed as definitely related to the study drug."

Shanghai Jiao Tong University School of Medicine announced July 26 that it had established a special task force to investigate the case. The institution said it would conduct a full review of research papers published by Qiu as well as the clinical study carried out at Xinhua Hospital.

For investors, the two deaths could trigger stricter compliance requirements for gene therapy and gene-editing clinical trials in China. Companies with AAV-based or gene-editing programs — including those targeting Duchenne muscular dystrophy and central nervous system indications — may face negative sentiment, potential trial holds, delayed approvals, and cautious valuations. The consecutive fatalities could also weigh on the broader gene-editing and cell therapy sectors globally, affecting clinical-stage biotech companies that rely on similar delivery platforms.

This article is for informational purposes only and does not constitute investment advice.